Literature DB >> 15778638

Utilities for prostate cancer health states in men aged 60 and older.

Susan T Stewart1, Leslie Lenert, Vibha Bhatnagar, Robert M Kaplan.   

Abstract

PURPOSE: We sought to measure utilities for prostate cancer health states in older men.
METHODS: A total of 162 men aged 60 years or older (52% of whom had been diagnosed with prostate cancer) provided standard gamble utilities for 19 health states associated with prostate cancer or its treatment using an interactive, computer-based utility assessment program. Demographics and experience with specific health states were examined as predictors of ratings using ordinary least squares regression analysis.
RESULTS: Mean utilities ranged from 0.67 to 0.84 for living with symptom-free cancer under conservative management ("watchful waiting") and from 0.71 to 0.89 for symptoms occurring with treatment (prostatectomy, radiation, and hormone ablation). For long-term treatment complications, bowel problems (0.71) were rated as significantly worse than impotence (0.89), urinary difficulty (0.88), or urinary incontinence (0.83). Combinations of these conditions were rated as significantly worse than individual component states. Men who had experienced impotence or urinary incontinence rated these states as slightly better than men who had not experienced the specific problems.
CONCLUSIONS: Both "watchful waiting" and treatment complications from prostate cancer treatments can have large impacts on quality of life. Mean ratings are important for use in policy-making and cost-effectiveness analyses. Variation in ratings across patients suggests that mean scores do not reflect individual preferences and that shared decision-making may be best for clinical decisions.

Entities:  

Mesh:

Year:  2005        PMID: 15778638     DOI: 10.1097/01.mlr.0000156862.33341.45

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  44 in total

1.  Variations in the quality of care at radical prostatectomy.

Authors:  Quoc-Dien Trinh; Jesse Sammon; Jay Jhaveri; Maxine Sun; Khurshid R Ghani; Jan Schmitges; Wooju Jeong; James O Peabody; Pierre I Karakiewicz; Mani Menon
Journal:  Ther Adv Urol       Date:  2012-04

2.  Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?

Authors:  S B Stewart; C D Scales; J W Moul; S D Reed
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-07-10       Impact factor: 5.554

3.  Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis.

Authors:  S P Elliott; T J Wilt; K M Kuntz
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-06-21       Impact factor: 5.554

4.  Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.

Authors:  Joshua A Roth; Roman Gulati; John L Gore; Matthew R Cooperberg; Ruth Etzioni
Journal:  JAMA Oncol       Date:  2016-07-01       Impact factor: 31.777

5.  Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.

Authors:  Shelby D Reed; Charles D Scales; Suzanne B Stewart; Jielin Sun; Judd W Moul; Kevin A Schulman; Jianfeng Xu
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

6.  Management of Active Surveillance-Eligible Prostate Cancer during Pretransplantation Workup of Patients with Kidney Failure: A Simulation Study.

Authors:  Uwe Bieri; Kerstin Hübel; Harald Seeger; Girish S Kulkarni; Tullio Sulser; Thomas Hermanns; Marian S Wettstein
Journal:  Clin J Am Soc Nephrol       Date:  2020-05-07       Impact factor: 8.237

7.  A Framework for Treatment Decision Making at Prostate Cancer Recurrence.

Authors:  Jane M Lange; Bruce J Trock; Roman Gulati; Ruth Etzioni
Journal:  Med Decis Making       Date:  2017-05-31       Impact factor: 2.583

8.  Health utility scores of colorectal cancer based on societal preference in Japan.

Authors:  Takeru Shiroiwa; Takashi Fukuda; Kiichiro Tsutani
Journal:  Qual Life Res       Date:  2009-07-21       Impact factor: 4.147

9.  Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.

Authors:  Julia H Hayes; Daniel A Ollendorf; Steven D Pearson; Michael J Barry; Philip W Kantoff; Pablo A Lee; Pamela M McMahon
Journal:  Ann Intern Med       Date:  2013-06-18       Impact factor: 25.391

10.  Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.

Authors:  Salimah H Meghani; Christopher S Lee; Alexandra L Hanlon; Deborah W Bruner
Journal:  BMC Med Inform Decis Mak       Date:  2009-11-27       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.